专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120004251A1 USE OF THE PHYTOCANNABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY 有权
标题翻译：利多卡因胆碱（CBDV）在治疗急性胰腺炎中的应用
公开(公告)号：US20120004251A1
公开(公告)日：2012-01-05
申请号：US13075873
申请日：2011-03-30
申请人： Ben Whalley , Claire Williams , Gary Stephens , Takashi Futamura
发明人： Ben Whalley , Claire Williams , Gary Stephens , Takashi Futamura
IPC分类号： A61K31/515 , A61P25/08 , A61K31/4015 , A61K31/19 , A61K31/05 , A61K31/352
CPC分类号： A61K31/05 , A61K31/19 , A61K31/352 , A61K31/40 , A61K31/515 , A61K36/185 , A61K45/06 , A61K2300/00
摘要： This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
摘要翻译：本发明涉及植物大麻素大麻素（CBDV）和植物大麻素CBDV与四氢大麻素（THCV）和大麻二醇（CBD）的组合在治疗癫痫中的用途。本发明还涉及植物大麻素CBDV与标准抗癫痫药（SAED）的组合的用途。优选地，SAED是乙酰亚胺，丙戊酸盐或苯巴比妥之一。

2. 发明申请

US20140155456A9 USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY 审中-公开
标题翻译：在治疗癫痫药物中使用标准抗真菌药物（SAED）联合生物素化胆碱酯（CBD）
公开(公告)号：US20140155456A9
公开(公告)日：2014-06-05
申请号：US13977766
申请日：2012-01-03
申请人： Ben Whalley , Claire Williams , Gary Stephens
发明人： Ben Whalley , Claire Williams , Gary Stephens
IPC分类号： A61K31/05 , A61K31/4015 , A61K31/19 , A61K45/06
CPC分类号： A61K31/05 , A61K31/19 , A61K31/352 , A61K31/4015 , A61K31/515 , A61K36/00 , A61K45/06 , A61K2300/00
摘要： The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.
摘要翻译：本发明涉及以大于300mg /天的剂量与通过钠或钙通道作用的标准抗癫痫药（SAED）组合的大麻二酚（CBD）的用途，用于治疗癫痫。 SAED优选是修改低阈值或瞬时神经元钙电流，或者降低高频神经元激发和钠依赖性动作电位并增强GABA效应。优选的SAED是乙酰亚胺和丙戊酸。

3. 发明授权

US09125859B2 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy 有权
标题翻译：使用植物大麻素大麻素（CBDV）治疗癫痫
公开(公告)号：US09125859B2
公开(公告)日：2015-09-08
申请号：US13075873
申请日：2011-03-30
申请人： Ben Whalley , Claire Williams , Gary Stephens , Takashi Futamura
发明人： Ben Whalley , Claire Williams , Gary Stephens , Takashi Futamura
IPC分类号： A61K31/05 , A61K31/19 , A61K31/352 , A61K31/40 , A61K36/185 , A61K45/06
CPC分类号： A61K31/05 , A61K31/19 , A61K31/352 , A61K31/40 , A61K31/515 , A61K36/185 , A61K45/06 , A61K2300/00
摘要： This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
摘要翻译：本发明涉及植物大麻素大麻素（CBDV）和植物大麻素CBDV与四氢大麻素（THCV）和大麻二醇（CBD）的组合在治疗癫痫中的用途。本发明还涉及植物大麻素CBDV与标准抗癫痫药（SAED）的组合的用途。优选地，SAED是乙酰亚胺，丙戊酸盐或苯巴比妥之一。

4. 发明授权

US09066920B2 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy 有权
标题翻译：使用植物大麻素的一种或其组合治疗癫痫
公开(公告)号：US09066920B2
公开(公告)日：2015-06-30
申请号：US13380305
申请日：2010-06-29
申请人： Ben Whalley , Gary Stephens , Claire Williams , Geoffrey Guy , Stephen Wright , Tetsuro Kikuchi
发明人： Ben Whalley , Gary Stephens , Claire Williams , Geoffrey Guy , Stephen Wright , Tetsuro Kikuchi
IPC分类号： A61K31/352 , A61K31/05
CPC分类号： A61K31/05 , A61K31/352
摘要： This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
摘要翻译：本发明涉及一种或多种大麻素用于治疗癫痫的用途，更具体地说涉及使用一种或大麻素的组合来治疗广泛性或部分性发作。在一个实施方案中，其涉及大麻素THCV作为纯的或分离的化合物或作为其中显着量的任何THC天然存在的植物提取物的使用已被选择性地除去。在另一个实施方案中，植物大麻素是CBD。

5. 发明申请

US20130296398A1 USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY 审中-公开
标题翻译：在治疗癫痫药物中使用标准抗真菌药物（SAED）联合生物素化胆碱酯（CBD）
公开(公告)号：US20130296398A1
公开(公告)日：2013-11-07
申请号：US13977766
申请日：2012-01-03
申请人： Ben Whalley , Claire Williams , Gary Stephens
发明人： Ben Whalley , Claire Williams , Gary Stephens
IPC分类号： A61K31/05 , A61K31/4015 , A61K31/19 , A61K45/06
CPC分类号： A61K31/05 , A61K31/19 , A61K31/352 , A61K31/4015 , A61K31/515 , A61K36/00 , A61K45/06 , A61K2300/00
摘要： The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.
摘要翻译：本发明涉及以大于300mg /天的剂量与通过钠或钙通道作用的标准抗癫痫药（SAED）组合的大麻二酚（CBD）的用途，用于治疗癫痫。 SAED优选是修饰低阈值或瞬时神经元钙电流，或者降低高频神经元激发和钠依赖性动作电位并增强GABA作用。优选的SAED是乙酰亚胺和丙戊酸。

6. 发明申请

US20120165402A1 USE OF ONE OR A COMBINATION OF PHYTO-CANNABINOIDS IN THE TREATMENT OF EPILEPSY 有权
标题翻译：使用一种或将PHYTO-CANNABINOIDS组合在治疗EPILEPSY
公开(公告)号：US20120165402A1
公开(公告)日：2012-06-28
申请号：US13380305
申请日：2010-06-29
申请人： Ben Whalley , Gary Stephens , Claire Willaims , Geoffrey Guy , Stephen Wright , Tetsuro Kikuchi
发明人： Ben Whalley , Gary Stephens , Claire Willaims , Geoffrey Guy , Stephen Wright , Tetsuro Kikuchi
IPC分类号： A61K31/352 , A61P25/08 , A61K31/05
CPC分类号： A61K31/05 , A61K31/352
摘要： This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
摘要翻译：本发明涉及一种或多种大麻素用于治疗癫痫的用途，更具体地说涉及使用一种或大麻素的组合来治疗广泛性或部分性发作。在一个实施方案中，其涉及大麻素THCV作为纯的或分离的化合物或作为其中显着量的任何THC天然存在的植物提取物的使用已被选择性地除去。在另一个实施方案中，植物大麻素是CBD。

7. 发明申请

US20140243405A1 A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) 审中-公开
标题翻译：含有PHYCOCANNABINOID CANNABIDIVARIN（CBDV）和CANNABIDIOL（CBD）的药物组合物
公开(公告)号：US20140243405A1
公开(公告)日：2014-08-28
申请号：US14345968
申请日：2012-09-14
申请人： Benjamin Whalley , Claire Williams , Gary Stephens
发明人： Benjamin Whalley , Claire Williams , Gary Stephens
IPC分类号： A61K31/05 , A61K31/353 , A61K45/06
摘要： This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC). More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and/or CBD.
摘要翻译：本发明涉及包含或基本上由植物大麻素大麻素（CBDV）和大麻二酚（CBD）组成的药物组合物。该组合物特别安全和有效地用于治疗神经系统疾病，其特征在于中枢神经系统的兴奋性高，惊厥或惊厥如癫痫发作。优选地，CBDV和CBD存在至少一种大麻素的非大麻素成分，例如一种或多种萜烯或萜烯级分。更具体地，组合物还包含一种或多种大麻染料型化合物。特别是异丙基丙基变体（CBCV）和/或大麻色素（CBC）。更具体地，组合物不存在或基本上不含其他大麻素，包括特别是四氢大麻酚（THC）和四氢大麻素（THCV），其通常以大量化学型存在，以含有显着量的CBDV和/或CBD 。

8. 发明授权

US10729665B2 Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) 有权
公开(公告)号：US10729665B2
公开(公告)日：2020-08-04
申请号：US14345968
申请日：2012-09-14
申请人： Benjamin Whalley , Claire Williams , Gary Stephens , Thomas Hill
发明人： Benjamin Whalley , Claire Williams , Gary Stephens , Thomas Hill
IPC分类号： A61K31/352 , A61K31/05 , A61K36/185 , A61K31/045 , A61K31/353 , A61K45/06
摘要： This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC). More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and/or CBD.

9. 发明申请

US20120033801A1 Wireless Priority Service within a Distributed Call Processing Architecture 有权
标题翻译：分布式呼叫处理架构内的无线优先级服务
公开(公告)号：US20120033801A1
公开(公告)日：2012-02-09
申请号：US12951240
申请日：2010-11-22
申请人： Michael Mertz , Gary Stephens , Mahmud Alam , Mark Hebert , Robert Swanson , Roy Smith
发明人： Michael Mertz , Gary Stephens , Mahmud Alam , Mark Hebert , Robert Swanson , Roy Smith
IPC分类号： H04M3/42
CPC分类号： H04W28/08 , H04M2242/04 , H04W4/90 , H04W28/16 , H04W72/0426 , H04W72/10 , H04W76/50
摘要： A system, method, and call processing component for controlling an order of call processing among a plurality of call processing components. Each call processing component, upon receiving a call request when system resources are not available to process the requested call, creates a real queue entry in its call processing queue and sends a call-queued notification to all other call processing components in the system. The other call processing components in the telecommunication system then create a shadow queue entry in their respective call processing queues as a placeholder for the requested call. When system resources become available and the requested call is next in the queue, the call processing component that received the request de-queues and processes the requested call, and sends a call de-queued notification to the other call processing components. In response, each of the other call processing components removes the placeholder queue entry for the requested call from each call processing component's call processing queue.
摘要翻译：一种用于控制多个呼叫处理组件之间的呼叫处理顺序的系统，方法和呼叫处理组件。当系统资源不可用于处理所请求的呼叫时，每个呼叫处理组件在接收到呼叫请求时，在其呼叫处理队列中创建一个真实的队列条目，并将呼叫排队的通知发送到系统中的所有其他呼叫处理组件。电信系统中的其他呼叫处理组件然后在其各自的呼叫处理队列中创建一个影子队列条目作为所请求呼叫的占位符。当系统资源变得可用并且所请求的呼叫在下一个队列中时，接收到请求的呼叫处理组件对队列进行排队并处理所请求的呼叫，并且向其他呼叫处理组件发送呼叫去排队通知。作为响应，每个其他呼叫处理组件从每个呼叫处理组件的呼叫处理队列中去除所请求的呼叫的占位符队列条目。

10. 发明授权

US08634832B2 Mobile location recovery for MSC pooling 有权
标题翻译： MSC集合的移动位置恢复
公开(公告)号：US08634832B2
公开(公告)日：2014-01-21
申请号：US12951549
申请日：2010-11-22
申请人： Robert Swanson , Gary Stephens , Mahmud Alam , Mark Hebert , Michael Mertz , Roy Smith
发明人： Robert Swanson , Gary Stephens , Mahmud Alam , Mark Hebert , Michael Mertz , Roy Smith
IPC分类号： H04W4/00 , H04W24/00 , H04W68/00 , H04W24/02 , H04W24/04
CPC分类号： H04W24/04 , H04W8/08 , H04W60/04 , H04W88/14
摘要： An entity of a wireless telecommunications network having a pool of Mobile Switching Centers (MSCs) and a Home Location Register (HLR). The entity includes a network interface which sends pages to mobiles associated with a failed MSC of the pool of MSC's and experiencing termination isolation and receives responses to the pages from at least some of the mobiles. The entity includes a processing unit which produces a registration having updated location information for each response received by the network interface, the registration sent from the network interface to the HLR to end each mobile's termination isolation for which a response was received by the network interface. A method of an entity of a wireless telecommunications network having a pool of Mobile Switching Centers (MSCs) and a Home Location Register (HLR).
摘要翻译：具有移动交换中心（MSC）池和归属位置寄存器（HLR）的无线电信网络的实体。该实体包括网络接口，该网络接口将页面发送到与MSC的池的故障MSC相关联的移动台并且经历终止隔离并且从至少一些移动台接收对该页面的响应。该实体包括处理单元，该处理单元产生具有针对由网络接口接收的每个响应的更新的位置信息的注册，从网络接口发送到HLR的注册，以结束网络接口接收到响应的每个移动终端隔离。一种具有移动交换中心（MSC）池和归属位置寄存器（HLR）的无线电信网络的实体的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式